These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10610497)

  • 21. In vitro and in vivo activity of voriconazole and benznidazole combination on trypanosoma cruzi infection models.
    Gulin JEN; Eagleson MA; López-Muñoz RA; Solana ME; Altcheh J; García-Bournissen F
    Acta Trop; 2020 Nov; 211():105606. PubMed ID: 32598923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined treatment of heterocyclic analogues and benznidazole upon Trypanosoma cruzi in vivo.
    Batista Dda G; Batista MM; de Oliveira GM; Britto CC; Rodrigues AC; Stephens CE; Boykin DW; Soeiro Mde N
    PLoS One; 2011; 6(7):e22155. PubMed ID: 21814568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistant mice lacking interleukin-12 become susceptible to Trypanosoma cruzi infection but fail to mount a T helper type 2 response.
    Galvão Da Silva AP; Jacysyn JF; De Almeida Abrahamsohn I
    Immunology; 2003 Feb; 108(2):230-7. PubMed ID: 12562332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.
    Gruendling AP; Massago M; Teston AP; Monteiro WM; Kaneshima EN; Araújo SM; Gomes ML; Barbosa Md; Toledo MJ
    Am J Trop Med Hyg; 2015 Jun; 92(6):1178-89. PubMed ID: 25940197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
    Martins HR; Silva RM; Valadares HM; Toledo MJ; Veloso VM; Vitelli-Avelar DM; Carneiro CM; Machado-Coelho GL; Bahia MT; Martins-Filho OA; Macedo AM; Lana M
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3282-9. PubMed ID: 17638698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
    Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
    Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Could phenothiazine-benznidazole combined chemotherapy be effective in controlling heart parasitism and acute infectious myocarditis?
    Mendonça AAS; Gonçalves-Santos E; Souza-Silva TG; González-Lozano KJ; Caldas IS; Gonçalves RV; Diniz LF; Novaes RD
    Pharmacol Res; 2020 Aug; 158():104907. PubMed ID: 32416214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergism between tumor necrosis factor-alpha and interferon-gamma on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism.
    Muñoz-Fernández MA; Fernández MA; Fresno M
    Eur J Immunol; 1992 Feb; 22(2):301-7. PubMed ID: 1537373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions.
    Caldas IS; Talvani A; Caldas S; Carneiro CM; de Lana M; da Matta Guedes PM; Bahia MT
    Parasitol Res; 2008 Jul; 103(2):413-21. PubMed ID: 18454349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet-activating factor induces nitric oxide synthesis in Trypanosoma cruzi-infected macrophages and mediates resistance to parasite infection in mice.
    Aliberti JC; Machado FS; Gazzinelli RT; Teixeira MM; Silva JS
    Infect Immun; 1999 Jun; 67(6):2810-4. PubMed ID: 10338485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benznidazole, itraconazole and their combination in the treatment of acute experimental chagas disease in dogs.
    Cunha ELA; Torchelsen FKVDS; Cunha LM; de Oliveira MT; Fonseca KDS; Vieira PMA; Carneiro CM; de Lana M
    Exp Parasitol; 2019 Sep; 204():107711. PubMed ID: 31254494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.
    Seguel V; Castro L; Reigada C; Cortes L; Díaz MV; Miranda MR; Pereira CA; Lapier M; Campos-Estrada C; Morello A; Kemmerling U; Maya JD; López-Muñoz R
    Exp Parasitol; 2016 Dec; 171():23-32. PubMed ID: 27729250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trypanosoma cruzi: Induction of benznidazole resistance in vivo and its modulation by in vitro culturing and mice infection.
    Dos Santos FM; Caldas S; de Assis Cáu SB; Crepalde GP; de Lana M; Machado-Coelho GL; Veloso VM; Bahia MT
    Exp Parasitol; 2008 Dec; 120(4):385-90. PubMed ID: 18823980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
    Campos RF; Guerreiro ML; Sobral Kde S; Lima Rde C; Andrade SG
    Rev Soc Bras Med Trop; 2005; 38(2):142-6. PubMed ID: 15821788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myocardial scars correlate with eletrocardiographic changes in chronic Trypanosoma cruzi infection for dogs treated with Benznidazole.
    Caldas IS; da Matta Guedes PM; dos Santos FM; de Figueiredo Diniz L; Martins TA; da Silva do Nascimento AF; Azevedo MA; de Lima WG; Neto RM; Torres RM; Talvani A; Bahia MT
    Trop Med Int Health; 2013 Jan; 18(1):75-84. PubMed ID: 23107306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trypanosoma cruzi: effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice.
    Francisco AF; de Abreu Vieira PM; Arantes JM; Pedrosa ML; Martins HR; Silva M; Veloso VM; de Lana M; Bahia MT; Tafuri WL; Carneiro CM
    Exp Parasitol; 2008 Dec; 120(4):314-9. PubMed ID: 18789321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure.
    Romanha AJ; Alves RO; Murta SM; Silva JS; Ropert C; Gazzinelli RT
    J Infect Dis; 2002 Sep; 186(6):823-8. PubMed ID: 12198617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 4-nitrobenzoylcoumarin potentiates the antiparasitic, anti-inflammatory and cardioprotective effects of benznidazole in a murine model of acute Trypanosoma cruzi infection.
    Vilas-Boas DF; Oliveira RRG; Gonçalves-Santos E; Silva LS; Diniz LF; Mazzeti AL; Brancaglion GA; Carvalho DT; Caldas S; Novaes RD; Caldas IS
    Acta Trop; 2022 Apr; 228():106314. PubMed ID: 35038424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease.
    Oliveira-Silva JC; Machado-de-Assis GF; Oliveira MT; Paiva NC; Araújo MS; Carneiro CM; Martins-Filho OA; Martins HR; Lana Md
    Mem Inst Oswaldo Cruz; 2015 Feb; 110(1):86-94. PubMed ID: 25742267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.
    Bustamante JM; Craft JM; Crowe BD; Ketchie SA; Tarleton RL
    J Infect Dis; 2014 Jan; 209(1):150-62. PubMed ID: 23945371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.